All are sho and rapid acting insulin except ?
**Core Concept:** Insulin is a hormone secreted by the beta cells of the pancreas that plays a crucial role in regulating blood glucose levels. Insulin can be broadly classified into rapid-acting and long-acting types, with rapid-acting insulins acting within minutes and providing short-term glycaemic control. Rapid-acting insulins include regular insulin, aspart, lispro, glulisine, and glargine.
**Why the Correct Answer is Right:** NPH insulin (neutral protamine Hagedorn) is a long-acting insulin preparation that is used for basal insulin requirements. It has a slow absorption rate and a long duration of action, which makes it unsuitable for immediate glycaemic control.
**Why Each Wrong Option is Incorrect:**
A. Regular insulin is a rapid-acting insulin type that is used for both basal and prandial (mealtime) insulin requirements. It has a short half-life and is suitable for immediate glycaemic control.
B. Lispro insulin is a rapid-acting insulin type that is designed for immediate glycaemic control. It is a short-acting insulin that works within 15 minutes and has a duration of action of 4-6 hours.
C. Glulisine insulin is another rapid-acting insulin type that works within 15 minutes and has a duration of action of 4-6 hours. It is similar to lispro insulin and is used for immediate glycaemic control.
D. Glargine insulin is a long-acting insulin type used for basal insulin requirements. It has a slow absorption rate and a duration of action of up to 24 hours. This makes it unsuitable for immediate glycaemic control.
**Clinical Pearl:** The choice of an insulin type depends on the timing and duration of action required. Rapid-acting insulins, like lispro and glulisine, are suitable for immediate glycaemic control, while long-acting insulins, like glargine and NPH, are suitable for basal insulin requirements.
**Core Concept:** The correct insulin type should be chosen based on the timing and duration of action required, ensuring that the patient achieves optimal glycaemic control without hypoglycaemic episodes.